Affimed

Traded on the St. Petersburg Stock Exchange
Affimed N.V. is a clinical-stage biopharmaceutical company that develops immunotherapies for cancer based on its proprietary ROCK platform. It was founded in 2000 under the name Affimed Therapeutics BV, and changed it to its current name in October 2014. It is headquartered in Heidelberg, Germany.
Affimed stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Affimed balance sheet

Report period2017 2018201920202021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Affimed cash flows

Report period2017 2018201920202021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Affimed multipliers

Report period2017 2018201920202021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Affimed profitability

Report period2017 2018201920202021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Affimed assets
Affimed cash flows

Affimed dividend policy

The company doesn't provide dividends

Affimed shares

TickerNameTypeNominal valueISINPrice
AFMD:USAffimedCommon share-NL0010872420$3.63
General information
Company nameAffimed
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressTechnologiepark Im Neuenheimer Feld 582 Heidelberg 69120 Germany
Mailing addressTechnologiepark Im Neuenheimer Feld 582 Heidelberg 69120 Germany
Websitewww.affimed.com